Ibrutinib for chronic graft-versus-host disease after failure of prior therapy-Reference-Cited by-同舟云学术

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Published:2017-11-23 Issue:21 Volume:130 Page:2243-2250
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Miklos David¹,Cutler Corey S.²,Arora Mukta³,Waller Edmund K.⁴,Jagasia Madan⁵,Pusic Iskra⁶,Flowers Mary E.⁷,Logan Aaron C.⁸,Nakamura Ryotaro⁹,Blazar Bruce R.³,Li Yunfeng¹⁰,Chang Stephen¹⁰,Lal Indu¹⁰,Dubovsky Jason¹⁰,James Danelle F.¹⁰,Styles Lori¹⁰,Jaglowski Samantha¹¹

Affiliation:

1. Stanford University School of Medicine, Stanford, CA;

2. Dana-Farber Cancer Institute, Boston, MA;

3. Department of Medicine, University of Minnesota, Minneapolis, MN;

4. Winship Cancer Institute of Emory University, Atlanta, GA;

5. Vanderbilt-Ingram Cancer Center, Nashville, TN;

6. Division of Oncology, Washington University School of Medicine, St. Louis, MO;

7. Fred Hutchinson Cancer Research Center, Seattle, WA;

8. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;

9. City of Hope, Duarte, CA;

10. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and

11. Division of Hematology, The Ohio State University Cancer Center, Columbus, OH

Abstract

Key Points Ibrutinib induced a high rate of sustained responses for patients with cGVHD and inadequate response to corticosteroid-containing therapy. This trial supported the approval of ibrutinib for treatment of adult patients with cGVHD after failure of ≥1 lines of systemic therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/21/2243/1403803/blood793786.pdf

Reference41 articles.

1. Have we made progress in the management of chronic graft-vs-host disease?;Lee;Best Pract Res Clin Haematol,2010

2. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis;Arora;Blood,2011

3. Long-term survival and late deaths after allogeneic bone marrow transplantation;Socié;N Engl J Med,1999

4. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse;Lee;Blood,2002

5. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study;Fraser;Blood,2006

Cited by 325 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions;Blood Advances;2024-02-13

2. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation;The Lancet Haematology;2024-02

3. Current Advances in Graft-versus-host Disease After Intestinal Transplantation;Transplantation;2024-01-19

4. How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review;Clinical & Experimental Ophthalmology;2024-01-10

5. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease;Nature Communications;2024-01-10